MK Proteins Limited has delivered impressive financial performance in Q3FY26, demonstrating strong operational growth across key metrics. The vegetable refined oil manufacturer reported substantial revenue expansion and maintained healthy profitability during the quarter ended December 31, 2025.

Financial Performance Overview

The company's quarterly results showcase remarkable revenue growth, with operations scaling significantly compared to the previous year. Total revenue including other income reached ₹8957.54 lacs in Q3FY26, representing a substantial increase from ₹3972.44 lacs in Q3FY25.

Operational Efficiency and Cost Management

The company's expenditure structure reflects the scaled operations, with total expenses rising to ₹8760.91 lacs in Q3FY26 from ₹3786.57 lacs in Q3FY25. Key expense components included cost of material consumed at ₹8569.66 lacs and purchase of stock-in-trade at ₹2569.96 lacs. Notably, the company benefited from a favorable change in inventories of ₹2734.84 lacs, which positively impacted the overall cost structure.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, MK Proteins demonstrated consistent growth momentum. Revenue from operations increased to ₹23693.46 lacs compared to ₹13050.19 lacs in the corresponding period of FY25. Net profit for nine months reached ₹569.07 lacs, marginally higher than ₹560.13 lacs achieved in 9MFY25.

Earnings Per Share and Capital Structure

The company maintained stable earnings per share metrics during the quarter. Basic and diluted earnings per share from continuing operations stood at ₹0.04 for Q3FY26, matching the ₹0.04 achieved in Q3FY25. The paid-up equity share capital remained unchanged at ₹3753.72 lacs with a face value of ₹1 per share.

Corporate Governance and Compliance

The unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 13, 2026. The results have been reviewed by statutory auditors Subhash Sajal & Associates as required under Regulation 33 of SEBI Listing Regulations. The company operates in a single business segment focused on manufacturing vegetable refined oil, with no separate reportable segments.

MK Proteins Limited has announced a board meeting scheduled for February 13, 2026, to review and approve the company's quarterly financial performance. The meeting will focus on considering the unaudited financial results for the quarter ended December 31, 2025, as part of the company's regular financial disclosure obligations.

Board Meeting Details

The board meeting has been scheduled in accordance with Regulation 29 of the SEBI (LODR) Regulations, 2015. The company has formally notified both stock exchanges about the upcoming meeting through official communications.

Trading Window Restrictions

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for prevention of Insider Trading, MK Proteins has implemented trading restrictions. The trading window for the company's equity shares will remain closed until the financial results are declared.

The trading window will reopen 48 hours after the declaration of the unaudited financial results, allowing shareholders and investors to resume trading activities based on the disclosed financial information.

Regulatory Compliance

The announcement demonstrates MK Proteins' adherence to regulatory requirements and corporate governance standards. The company has fulfilled its disclosure obligations by informing both the Bombay Stock Exchange and National Stock Exchange of India about the scheduled board meeting.

The formal communication was signed by Neha Aggarwal, Company Secretary & Compliance Officer, ensuring proper authorization and compliance with regulatory protocols. This scheduled meeting represents part of the company's regular quarterly financial reporting cycle, maintaining transparency with stakeholders and regulatory authorities.